Top Wall Street analysts have recently adjusted their outlooks on several prominent companies, including Blackstone, Virpax Pharmaceuticals, Daqo New Energy, and FactSet Research Systems. These changes involve both downgrades and price target adjustments, offering insights into the current market sentiment and potential investment strategies.
Daqo New Energy Corp. (DQ) reported disappointing second-quarter earnings, missing both revenue and earnings per share estimates. The company attributed the poor performance to a challenging solar industry environment characterized by falling market prices and oversupply. Despite this, Daqo remains optimistic about its long-term prospects and has announced a $100 million share repurchase program to bolster shareholder confidence.
